Study of AB122 and AB928 with Chemotherapy and Radiation for Rectal Cancer
This study is testing the safety and effectiveness of combining two new drugs, etrumadenant (AB928) and zimberelimab (AB122), with standard radiation and chemotherapy (FOLFOX) for rectal cancer. You would first receive short-course radiation therapy along with etrumadenant. This is followed by chemotherapy with FOLFOX, etrumadenant, and zimberelimab. After this, you may continue to receive zimberelimab for up to a year. The study is looking to see how many patients have a complete response to treatment. This study is for people aged 18 to 90 with a confirmed diagnosis of rectal adenocarcinoma. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 43 participants. It combines radiation therapy, chemotherapy, and two investigational drugs.
- What's involved
- You would receive radiation therapy for one week, followed by 9 cycles of chemotherapy over 18 weeks. After this, you would have assessments around week 22-24, including a digital rectal exam, MRI, and endoscopy, followed by surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, complete pathologic response, is measured at Week 24, after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05024097
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Recruiting
PHASE2Ages 18–90InterventionalTreatmentWeill Medical College of Cornell UniversityInvestigator-initiated
~43 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Etrumadenant (AB928)Radiation therapyFOLFOX regimenZimberelimab (AB122)
At a glance
Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of treated patients who achieve complete pathologic response
Measured over Week 24
Conditions
Where it's being run
3 sites across 1 statesNew York3
Study leadership
- Encouse Golden, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed diagnosis of adenocarcinoma of the rectum
Age ≥ 18 years
ECOG performance status 0-1
cT3N0 or cT1-3N1 or cT4 or cN2
5cm from the anal verge
Rectal cancer amenable to total mesorectal excision
No evidence of distant metastases
No prior pelvic radiation therapy
No prior chemotherapy or surgery for rectal cancer
No infections requiring systemic antibiotic treatment
Hgb \>8.0 gm/dL, PLT \> 150,000/mm3, total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal
Patients must read, agree to, and sign a statement of informed consent prior to participation in this study. Patients who do not read or understand English or eligible but must have the consent form bread to them in its entirety by an official translator. Informed consent for non-literate or non-English speaking patients may not be obtained by using a relative or a member of the patient's clinical team as a translator
Female participants or reproductive potential, defined as not surgically sterilized and between menarche and 1 year post menopause, must have a negative serum pregnancy test within 4 weeks prior to initiation of study treatment
Female participants of reproductive potential and male participants with female partners of reproductive potential must remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures from the start of study treatment until 30 days after the last dose of Etrumadenant, -120 days after the last dose of Zimberelimab, whichever is longer and duration of contraception to follow oxaliplatin should be at least 9 months after the last dose for women and 6 months after the last dose for men)
Women with childbearing potential who are negative for pregnancy (urine or blood) and who agree to use effective contraceptive methods. A woman of childbearing potential is defined by one who is biologically capable of becoming pregnant. Reliable contraception should be used from trial screening and must be continued throughout the study.
Male subjects must also agree to use effective contraception.
Exclusion
Recurrent rectal cancer
Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is demed to be adherent or fixed to adjacent pelvic structures (en bloc resection wll not be achieved with negative margins).
Involved radial margin
Serum creatinine level \>1.5x the upper limit of normal
Patients who have received prior pelvic radiotherapy
QTc ≥480 msec using Fredericia's QT correction formula
Due to the potential risk for drug-drug interactions with etrumadenant, participants must not have had:
Treatment with known BCRP substrates with a narrow therapeutic window, administered orally (e.g., prazosin, rosuvastatin) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of and throughout study treatment
Treatment with known P-gp substrates with a narrow therapeutic window, administered orally (e.g., digoxin) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of study treatment
Treatment with known strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort) and strong CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, telithromycin, and voriconazole) within 4 weeks (for investigational drugs when half- life is unknown or not accurately determined) or 5 drug-elimination half-lives of the drug (when half-life is determined), whichever is longer, or if it is a marketed drug, then 5 drug-elimination half-lives of the drug, prior to initiation of study treatment
Refer to the following for more examples of relevant substrates, inhibitors, and inducers with the potential for drug-drug interactions with Etrumadenant: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug- interactions-table-substrates-inhibitors-and- Inducers
Patients receiving herbal and natural remedies. Concomitant use of therapies that contain cannabinoids may be permitted based on the Investigator's discretion.
Sensitive substrates of BSEP, MATE1and OCT2.
Any gastrointestinal condition that would preclude the use of oral medications (e.g., difficulty swallowing, nausea, vomiting, or malabsorption)
Prior treatment with an agent targeting the adenosine pathway
Patients with prior allogenic stem cell or solid organ transplantation
Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy
Patients with history of idiopathic pulmonary fibrosis, pneumonitis, or interstitial lung disease
Patients receiving treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor-α agents) administered at \>10 mg/day prednisone or equivalent within 2 weeks prior to initiation of study treatment
Patients who received a live vaccine within 30 days
Patients who are known to have dihydropyrimidine dehydrogenase (DPD) deficiency
Patients with peripheral neuropathy Grade ≥ 2
History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins
Patients with a history of any arterial thrombitic event within the past 6 months,
Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment would make them inappropriate candidates for entry into this study
Patients with a history of prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
Patients with a history of thrombotic episodes, such as deep venous thrombosis, pulmonary embolus, MI or CVA occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
Patients receiving other anticancer or experimental therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibodiy therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody, or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.
Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to four weeks after the study.
What this trial measures
- Number of treated patients who achieve complete pathologic responseWeek 24
The primary endpoint is the proportion of treated rectal cancer patients who achieve a complete pathologic response. All patients will be offered surgical resection however those who achieve a clinical CR at the time of clinical response assessment may choose a non-operative management approach. Due to practicality the latter will be included as complete responders at the time of analysis for this trial.